SARS2 and COVID-19: Additionally, several other inhibitors, such as rac3j, rac3k and rac5c targeting SARS‐CoV PLpro in clinical and preclinical stages have been described elsewhere.[277] Among them, rac5c also have potent inhibitory effect on SARS2 PLpro, which might be deliberated as a potential therapeutic strategy for COVID‐19.[278] Another small molecule DDL‐701 is also an effective SARS2 PLpro inhibitor which displayed sustained inhibitory activity.[279]